Selpercatinib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Trial Timeline
— → —
NCT ID
NCT03906331About Selpercatinib
Selpercatinib is a pre-clinical stage product being developed by Eli Lilly for Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03906331. Target conditions include Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03906331 | Pre-clinical | Completed |
| NCT05324124 | Phase 1 | Completed |
| NCT05136404 | Phase 1 | Completed |
| NCT05089019 | Phase 1 | Completed |
| NCT04280081 | Phase 2 | Active |
| NCT03899792 | Phase 1/2 | Active |
| NCT05338515 | Phase 1 | Completed |
| NCT05469100 | Phase 1 | Completed |
| NCT05436912 | Phase 1 | Completed |
Competing Products
20 competing products in Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY2875358 + Erlotinib | Eli Lilly | Phase 2 | 52 |